Vasomotor Rhinitis

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
Cold-dry air provocationN/A1 trial
Active Trials
NCT00415493CompletedEst. May 2008
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
esomeprazoleN/ASmall Molecule1 trial
Active Trials
NCT00745849Completed43Est. Mar 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HELP TherapeuticsCold-dry air provocation
AstraZenecaesomeprazole

Clinical Trials (2)

Total enrollment: 43 patients across 2 trials

NCT00415493HELP TherapeuticsCold-dry air provocation

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

Start: Dec 2006Est. completion: May 2008
N/ACompleted

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

Start: Jun 2005Est. completion: Mar 200843 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space